Search
Linzagolix
go.drugbank.com/drugs/DB17083ApprovedInvestigational[A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627] … As these fibroids are essentially estrogen-dependent phenomena, hormone therapies which suppress estrogen activity - including GnRH receptor antagonists like linzagolix - are thought to be beneficial by
Celastrol
go.drugbank.com/drugs/DB18736ExperimentalCelastrol is a pentacyclic triterpenoid isolated from the root extracts of _Tripterygium wilfordii_.[L50567]
DiaPep 277
go.drugbank.com/drugs/DB06651InvestigationalDiaPep 277 is a 24-mer laboratory-made peptide derived from Hsp60(437-460).
N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide
go.drugbank.com/drugs/DB08559Experimentalfrom the sulfur atom at position 1]. … These are organic compounds containing the penicillin core structure, which is structurally characterized by a penam ring bearing two methyl groups at position 2, and an amide group at position 6 [starting
Synonyms: N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamideOP-145
go.drugbank.com/drugs/DB05672ExperimentalOP-145 is a synthetic antimicrobial peptide developed from human cathelicidin LL-37.
Brefeldin A
go.drugbank.com/drugs/DB07348ExperimentalA metabolite from Penicillium brefeldianum that exhibits a wide range of antibiotic activity.
Halcinonide
go.drugbank.com/drugs/DB06786ApprovedWithdrawnHalcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc.
Nesiritide
go.drugbank.com/drugs/DB04899ApprovedInvestigationalWithdrawnNesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing). Nesiritide is a 32 amino acid recombinant human B-type natriuretic p...
iCo-007
go.drugbank.com/drugs/DB05268InvestigationaliCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis
BW-A 58C
go.drugbank.com/drugs/DB06740Experimentala 54 kDa CYP2C9 form of cytochrome P450, P450hB20-27. … naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by